Bukwang Pharmaceutical Signs Strategic MOU with DreamCIS and AWS

Next-Generation Drug Development Based on AI and Organoid Technologies

Bukwang Pharmaceutical is partnering with DreamCIS, the number one clinical research organization (CRO) in Korea, and Amazon Web Services (AWS) to collaborate on next-generation new drug development based on artificial intelligence (AI) and organoid technologies.

On May 26, Bukwang Pharmaceutical announced that it had signed a memorandum of understanding (MOU) with the two companies for "organoid-based new alternative methods (NAMs) and AI-powered clinical drug development" at its headquarters in Dongjak-gu, Seoul.

Lee Jeyoung, CEO of Bukwang Pharmaceutical (center), Minseong Cho, Head of Healthcare at Amazon Web Services (AWS) (left), and Junghee Yoo, CEO of DreamCIS (right), are taking a commemorative photo at the AI and Organoid-Based New Drug Development Business Agreement Ceremony. Bukwang Pharmaceutical

The main aspects of the three-party agreement include joint research on organoid NAMs, optimization of clinical trial design using AI, co-development of a global unified R&D platform, and joint response to regulatory science. Organoids are miniature artificial organs created in the laboratory that replicate the structure and function of human organs. As a next-generation technology, they enable more accurate predictions of drug safety and efficacy by replacing animal testing.

Through this agreement, Bukwang Pharmaceutical will combine its new drug pipeline and clinical validation infrastructure with DreamCIS's organoid and CRO platforms and AWS's cloud and AI technologies. Bukwang Pharmaceutical aims to play a leading role in fundamentally transforming the paradigm of new drug development.

AWS supports innovation in new drug research and development by providing proven cloud infrastructure and AI services to thousands of healthcare and life sciences organizations worldwide. In this collaboration, AWS will offer technological capabilities across the entire drug development lifecycle, including large-scale molecular simulation data analysis, machine learning-based drug response prediction, and integrated management of clinical trial data.

The core value Bukwang Pharmaceutical pursues through this agreement is "simultaneous innovation in speed and safety." The greatest challenges in new drug development are the clinical failure rate caused by the limitations of animal testing and the lengthy development timelines.

The combination of the three companies will provide Bukwang Pharmaceutical with a one-stop system supporting all phases from preclinical (organoid and NAMs) to regulatory approval, clinical trials, and commercialization. Through this, Bukwang Pharmaceutical plans not only to improve the development efficiency of its proprietary pipeline, but also to expand its role as a hub for the introduction and validation of global innovative drugs in Korea.

Going forward, Bukwang Pharmaceutical will form a working group with the two companies and launch a joint pilot study linking organoid toxicity assessments with AWS AI data analysis. The results will be used as preclinical data packages for submission to regulatory authorities in Korea and abroad.

Jaeyoung Lee, CEO of Bukwang Pharmaceutical, stated, "This three-party agreement marks a turning point for Bukwang Pharmaceutical, elevating the company from a simple drug manufacturer to a leader in the next-generation new drug development ecosystem based on AI and organoid technology. We expect that combining DreamCIS's organoid technology and AWS's cloud and AI capabilities with Bukwang Pharmaceutical's pipeline will create an innovative structure that shortens development time and reduces costs while increasing the success rate. Ultimately, our goal is to find ways to provide patients with faster, safer, and more affordable treatments."

This content was produced with the assistance of AI translation services.